Categories
  Encyclosphere.org ENCYCLOREADER
  supported by EncyclosphereKSF

Senaparib

Topic: Chemistry

 From HandWiki - Reading time: 1 min

Senaparib is a drug that is being evaluated to treat various forms of cancer.[1] It is a PARP inhibitor.[2] In January 2025, senaparib was approved for use in China for treatment of advanced epithelial high-grade ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.[3]

References

  1. ↑ "Senaparib - IMPACT Therapeutics". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800049191. 
  2. ↑ "The discovery of a potent PARP1 inhibitor Senaparib". Molecular Cancer Therapeutics 24 (1): OF1–OF9. June 2024. doi:10.1158/1535-7163.MCT-23-0625. PMID 38920409. 
  3. ↑ "Senaparib Receives NMPA Approval As First-Line Maintenance in Ovarian Cancer". January 17, 2025. https://www.onclive.com/view/senaparib-receives-nmpa-approval-as-first-line-maintenance-in-ovarian-cancer. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Senaparib&oldid=4028556"
Licensed under CC BY-SA 3.0 | Source: https://handwiki.org/wiki/Chemistry:Senaparib
1 views |
↧ Download this article as ZWI file
Encyclosphere.org EncycloReader is supported by the EncyclosphereKSF